| Literature DB >> 31857597 |
Tomohito Sato1, Masaru Takeuchi2, Yoko Karasawa1, Kei Takayama1, Toshio Enoki3.
Abstract
Neovascular age-related macular degeneration (nAMD) is a complex and multi-factorial disease, and low-grade inflammation is associated with pathogenesis of nAMD. Aqueous humor could reflect intraocular immune environments in various eye diseases. The research so far used aqueous humor samples and revealed that inflammation is involved in pathophysiology of nAMD, although immunological roles of cytokines were evaluated inadequately with aspect to individual effects. Here we used 27 kinds of cytokines covering general immunologic reactions, examined specific expression patterns of cytokines, and assessed relationships between inflammation and pathophysiology of nAMD by multivariate analyses. In nAMD eyes, principal component analysis showed that IL-7, MCP-1, MIP-1β and VEGF had high principal component loadings of over 0.6 in the first principal component constituting 32.6% of all variability of the data. In exploratory factor analysis, IL-6, MCP-1 and MIP-1β had high factor loadings (FL) of over 0.5 in Factor 1 constituting 32.6% of all variability, while VEGF had FL of over 1.0 in Factor 3 constituting 10.7% of all variability. In hierarchical cluster analysis, MCP-1 and VEGF were located in the cluster of first proximate mutual distance to central retinal thickness. These data could suggest that low-grade inflammation is a principal contributor in nAMD.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31857597 PMCID: PMC6923359 DOI: 10.1038/s41598-019-55191-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of nAMD patients and controls.
| Category | nAMD | Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Typical | PCV | RAP | |||||
| Type 1 | Type 2 | |||||||
| 62 (100%) | 21 (34%) | 15 (24%) | 25 (40%) | 1 (2%) | 20 | Total nAMD | Among 4 groups | |
| Age (year) | 75# (46–94)† | 75 (55–88) | 77 (48–94) | 74 (46–94) | 81 | 72 (55–90) | 0.385 | 0.736 |
| Gender (M/F) | 41/21 | 16/5 | 9/6 | 15/10 | 1/0 | 8/12 | 0.070 | 0.134 |
Four groups comprised of type 1-, type 2- and PCV-nAMD groups and control group.
The comparison between total nAMD eyes and controls was examined by Mann-Whitney U test. The comparisons among 4 groups were examined by Kruskal-Wallis test. nAMD; neovascular age-related macular degeneration, PCV; polypoidal choroidal vasculopathy, RAP; retinal angiomatous proliferation, N; number, M; male, F; female, #; median, †; range.
Aqueous humor levels of cytokines in nAMD patients and controls.
| Category | nAMD | Control | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 | 20 | ||||||||||
| Detectable samples (%) | Value | Detectable samples (%) | Value | Cytokine detection range | |||||||
| Median | First quartile | Third quartile | Median | First quartile | Third quartile | Higer limit | Lower limit | ||||
| logMAR VA | 62 (100) | 0.301 | 0.523 | 0.155 | 20 (100) | 0.301 | 0.936 | 0.172 | — | — | 0.513 |
| CRT | 62 (100) | 276 | 361 | 243 | 20 (100) | 266 | 277 | 251 | — | — | 0.382 |
| PDGF-BB | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 22416 | 1.55 | — |
| IL-1β | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 7978 | 0.34 | — |
| IL-1ra | 5 (8.06) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 95441 | 5.73 | 0.509 |
| IL-2 | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 18043 | 0.67 | — |
| IL-4 | 0 (0) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 | 4478 | 0.15 | 0.523 |
| IL-5 | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 6143 | 0.61 | — |
| 41 (66.1) | 4.52 | 10.7 | 0 | 17 (85) | 40.5 | 145.4 | 6.00 | 36654 | 1.39 | ||
| IL-7 | 62 (100) | 8.54 | 12.5 | 5.82 | 20 (100) | 10.9 | 12.6 | 7.31 | 16433 | 0.64 | 0.231 |
| IL-8 | 40 (64.5) | 5.68 | 11.9 | 0 | 13 (65) | 5.72 | 9.68 | 0 | 28304 | 1.44 | 0.535 |
| IL-9 | 1 (1.61) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 | 28980 | 1.43 | 0.531 |
| IL-10 | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 27318 | 2.14 | — |
| IL-12 | 39 (62.9) | 7.60 | 13.9 | 0 | 15 (75) | 9.80 | 13.3 | 1.14 | 34353 | 2.38 | 0.402 |
| IL-13 | 39 (62.9) | 1.43 | 3.03 | 0 | 12 (60) | 1.61 | 2.91 | 0 | 8160 | 0.36 | 0.532 |
| IL-15 | 0 (0) | 0.30 | 0.52 | 0.15 | 0 (0) | 0 | 0 | 0 | 20231 | 1.38 | — |
| IL-17A | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 32486 | 2.17 | — |
| Eotaxin | 24 (38.7) | 0 | 5.88 | 0 | 4 (20) | 0 | 1.13 | 0 | 25274 | 1.26 | 0.268 |
| bFGF | 0 (0) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 | 4069 | 0.85 | 0.523 |
| G-CSF | 3 (4.84) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 | 39235 | 1.77 | 0.546 |
| GM-CSF | 0 (0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 13121 | 3.01 | — |
| IFN-γ | 1 (1.61) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 25411 | 3.35 | 0.539 |
| 62 (100) | 426.3 | 0 | 321.7 | 20 (100) | 245.2 | 344.5 | 81.6 | 34038 | 5.18 | ||
| MCP-1 | 62 (100) | 125.4 | 191.7 | 101.5 | 20 (100) | 227.5 | 273.0 | 87.4 | 13389 | 1.29 | 0.268 |
| MIP-1α | 16 (25.8) | 0 | 0.85 | 0 | 5 (25) | 0 | 0.96 | 0 | 1064 | 0.28 | 0.538 |
| MIP-1β | 62 (100) | 27.3 | 47.1 | 17.2 | 20 (100) | 29.2 | 49.9 | 19.1 | 12973 | 0.28 | 0.457 |
| RANTES | 0(0) | 0 | 0 | 0 | 0(0) | 0 | 0 | 0 | 4046 | 1.14 | — |
| TNFα | 0(0) | 0 | 0 | 0 | 0 (0) | 0 | 0 | 0 | 59069 | 3.25 | — |
| VEGF | 62 (100) | 110.5 | 171.2 | 54.7 | 20 (100) | 121.6 | 202.2 | 94.1 | 38764 | 1.63 | 0.182 |
Cytokine values are given in units of pg/mL. Cytokine levels were compared between nAMD eyes and controls by Mann-Whitney U test. CRT; central retinal thickness, PDGF-BB; platelet derived growth factor BB, IL-1ra; IL-1 receptor antagonist, bFGF; basic fibroblast growth factor, G-CSF; granulocyte colony-stimulating factor, GM-CSF; granulocyte-macrophage colony-stimulating factor, IP-10; interferon gamma-induced protein 10, MCP-1; monocyte chemoattractant protein-1, MIP-1α; macrophage inflammatory protein-1α, RANTES; regulated on activation, normal T-cell expressed and secreted, TNFα; tumor necrosis factor-α, VEGF; vascular endothelial growth factor. **P < 0.01.
Comparisons of cytokine levels in aqueous humor among nAMD subtypes and controls.
| Category | nAMD | Control | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subtype | Type 1 | Type 2 | PCV | 20 | Among 4 groups | Control vs. | Type 1 vs. | Type 2 vs. | |||
| 21 | 15 | 25 | Type 1 | Type 2 | PCV | Type 2 | PCV | PCV | |||
| Value | Median | ||||||||||
| 0.222 | 1.046 | 0.222 | 0.301 | 0.646 | 0.292 | 0.574 | 1.000 | ||||
| 259 | 395 | 260 | 266 | 0.999 | 0.972 | 0.051 | 0.698 | ||||
| Gender (M/F) | 16/5 | 9/6 | 15/10 | 8/12 | 0.134 | 0.407 | 0.301 | 0.501 | 0.395 | 0.739 | |
| PDGF-BB | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| IL-1β | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| IL-1ra | 0 | 0 | 0 | 0 | 0.404 | 0.761 | 0.344 | 0.573 | 0.764 | 0.961 | 0.950 |
| IL-2 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| IL-4 | 0 | 0 | 0 | 0 | 0.384 | 0.733 | 0.821 | 0.676 | — | — | — |
| IL-5 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| 4.34 | 9.24 | 4.27 | 40.5 | 0.777 | 0.994 | 0.673 | |||||
| 12.0 | 10.2 | 7.97 | 10.9 | 0.995 | 0.989 | 0.999 | 0.175 | 0.105 | |||
| IL-8 | 5.68 | 6.19 | 5.29 | 5.72 | 0.759 | 0.872 | 0.976 | 0.971 | 0.999 | 0.767 | 0.936 |
| IL-9 | 0 | 0 | 0 | — | 0.427 | 0.733 | 0.995 | 0.676 | 0.635 | — | 0.566 |
| IL-10 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| IL-12 | 9.22 | 10.6 | 0 | 9.80 | 0.170 | 0.961 | 0.985 | 0.273 | 0.807 | 0.655 | 0.178 |
| IL-13 | 1.54 | 2.86 | 1.11 | 1.61 | 0.283 | 0.987 | 0.538 | 0.852 | 0.880 | 0.791 | 0.204 |
| IL-15 | 0 | 0 | 0.22 | 0 | — | — | — | — | — | — | — |
| IL-17A | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| Eotaxin | 0 | 0 | 0 | 0 | 0.554 | 0.792 | 0.643 | 0.512 | 0.987 | 0.976 | 0.999 |
| bFGF | 0 | 0 | 0 | 0 | 0.384 | 0.733 | 0.821 | 0.676 | — | — | — |
| G-CSF | 0 | 0 | 0 | 0 | 0.506 | 0.929 | 0.995 | 0.676 | 0.995 | 0.399 | 0.566 |
| GM-CSF | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| IFN-γ | 0 | 0 | 0 | 0 | 0.524 | — | — | 0.806 | — | 0.794 | 0.865 |
| 430.6 | 737.6 | 389.1 | 245.2 | 0.329 | 1.000 | 0.388 | |||||
| MCP-1 | 121.2 | 170.2 | 131.2 | 227.5 | 0.315 | 0.574 | 0.997 | 0.573 | 0.479 | 0.989 | 0.578 |
| MIP-1α | 0 | 0 | 0 | 0 | 0.870 | 0.992 | 0.982 | 0.993 | 0.907 | 1.000 | 0.836 |
| MIP-1β | 25.6 | 32.1 | 28.0 | 29.2 | 0.805 | 0.953 | 0.987 | 0.825 | 0.983 | 0.998 | 0.841 |
| RANTES | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| TNFα | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — |
| VEGF | 118.5 | 153.2 | 74.2 | 121.6 | 0.071 | 0.796 | 0.941 | 0.068 | 0.759 | 0.637 | 0.187 |
LogMAR VA, CRT and cytokine levels were compared among 4 groups by Kruskal-Wallis test followed by post-hoc Steel–Dwass test for each comparison. *P < 0.05, **P < 0.01.
Figure 1Binomial logistic regression analysis of the contribution of aqueous humor cytokines to pathogenesis of nAMD. Risk factors of developing nAMD are shown in forest plot (A) and summary table (B) by binomial logistic regression analysis. CI; confidence interval, OR; odds ratio, *P < 0.05.
Figure 2Expression patterns of aqueous humor cytokines by principal component analysis in nAMD patients and controls. Biplots of principal component loading (PCL) in first principle component (PC1) and second principle component (PC2) of nAMD patients (A) or controls (D) are presented. PCLs of the PC1 and PC2 in nAMD patients (B) or controls (E) are shown. Eigenvalues, contribution rates (CR) and cumulative contribution rates (CCR) of PC1 and PC2 in nAMD patients (C) or controls (F) are described. CCR; cumulative contribution ratio, CR; contribution ratio, PC; principle component, PCL; principal component loading, PC1; first principle component, PC2; second principle component.
Figure 3Expression patterns of aqueous humor cytokines by exploratory factor analysis in nAMD patients. (A–C) Factor loadings (FL) of Factor1 (F1), Factor2 (F2) and Factor3 (F3) in nAMD eyes are drawn. (D–F) Biplots of FLs in F1, F2 and F3 are presented. (G) 3D-plots of FLs in F1, F2 and F3 are shown. (H) Eigenvalues, contribution rates and cumulative contribution rates of F1, F2 and F3 are described.
Figure 4Expression patterns of aqueous humor cytokines by hierarchical cluster analysis in nAMD patients and controls. Heat maps of inflammatory cytokines in aqueous humor of nAMD patients (A) and controls (B) are presented. Color scale of cytokine levels denotes the following: low cytokine levels, red; middle to high cytokine levels, black to green.
Correlations among best correlated visual acuity, central retinal thickness and levels of aqueous humor cytokines in nAMD patients.
| nAMD | Multiple regression analysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62 | ||||||||||||
| R | 0.584 | 0.580 | ||||||||||
| R2 | 0.341 | 0.336 | ||||||||||
| 0.314 | 0.0005 | 2.348 | 0.316 | 37.65 | 2.348 | |||||||
| IL-6 | 0.082 | 0.005 | 0.563 | 0.576 | IL-6 | −0.091 | 1.272 | −0.619 | 0.538 | |||
| IL-7 | 0.073 | 0.018 | 0.404 | 0.688 | IL-7 | 0.091 | 5.137 | 0.501 | 0.619 | |||
| IL-8 | −0.023 | 0.009 | −0.145 | 0.885 | IL-8 | −0.207 | 2.494 | −1.346 | 0.184 | |||
| IL-12 | −0.328 | 0.015 | −1.435 | 0.157 | IL-12 | 0.237 | 4.196 | 1.022 | 0.312 | |||
| 0.326 | 0.038 | 2.025 | IL-13 | 0.080 | 11.180 | 0.479 | 0.634 | |||||
| Eotaxin | 0.057 | 0.016 | 0.456 | 0.650 | Eotaxin | −0.096 | 4.565 | −0.760 | 0.451 | |||
| IP-10 | 0.034 | 0.0001 | 0.251 | 0.803 | IP-10 | 0.171 | 0.026 | 1.287 | 0.204 | |||
| MCP-1 | -0.082 | 0.001 | -0.363 | 0.718 | 0.514 | 0.219 | 2.382 | |||||
| MIP-1β | -0.108 | 0.005 | -0.602 | 0.550 | MIP-1β | −0.139 | 1.351 | −0.774 | 0.443 | |||
| 0.489 | 0.001 | 2.465 | −0.455 | 0.211 | −2.263 | |||||||
| logMAR VA | 1.000 | 0.164 | 0.266 | 0.207 | 0.048 | 0.078 | 0.130 | 0.138 | 0.176 | 0.186 | 0.037 | 0.175 |
| CRT | 0.164 | 1.000 | 0.006 | 0.031 | −0.085 | 0.021 | 0.046 | 0.003 | 0.185 | 0.049 | −0.071 | −0.108 |
| IL-6 | 0.266 | 0.006 | 1.000 | 0.381 | −0.048 | 0.028 | 0.037 | 0.292 | 0.080 | |||
| IL-7 | 0.207 | 0.031 | 0.381 | 1.000 | 0.131 | 0.342 | 0.214 | |||||
| IL-8 | 0.048 | −0.085 | 1.000 | −0.101 | 0.071 | 0.005 | 0.338 | 0.389 | 0.011 | |||
| IL-12 | 0.078 | 0.021 | −0.048 | −0.101 | 1.000 | 0.319 | −0.039 | −0.313 | 0.318 | |||
| IL-13 | 0.130 | 0.046 | 0.028 | 0.071 | 1.000 | 0.096 | 0.105 | −0.312 | 0.298 | 0.107 | ||
| Eotaxin | 0.138 | 0.003 | 0.037 | 0.131 | 0.005 | 0.319 | 0.096 | 1.000 | −0.080 | 0.042 | −0.023 | 0.292 |
| IP-10 | 0.176 | 0.185 | 0.342 | 0.338 | −0.039 | 0.105 | −0.080 | 1.000 | 0.357 | 0.283 | 0.060 | |
| MCP-1 | 0.186 | 0.049 | 0.214 | 0.389 | −0.313 | −0.312 | 0.042 | 0.357 | 1.000 | 0.287 | 0.190 | |
| MIP-1β | 0.037 | −0.071 | 0.292 | 0.318 | 0.298 | −0.023 | 0.283 | 0.287 | 1.000 | 0.390 | ||
| VEGF | 0.175 | −0.108 | 0.080 | 0.011 | 0.107 | 0.292 | 0.060 | 0.190 | 0.390 | 1.000 | ||
| logMAR VA | — | 0.202 | 0.107 | 0.710 | 0.549 | 0.315 | 0.285 | 0.172 | 0.148 | 0.776 | 0.174 | |
| CRT | — | 0.962 | 0.812 | 0.512 | 0.871 | 0.721 | 0.982 | 0.151 | 0.708 | 0.582 | 0.402 | |
| IL-6 | * | — | 0.709 | 0.826 | 0.778 | 0.538 | ||||||
| IL-7 | ** | — | 4.08 × 10 | 0.310 | 0.095 | |||||||
| IL-8 | ** | ** | — | 0.437 | 0.585 | 0.972 | 0.934 | |||||
| IL-12 | ** | — | 0.766 | |||||||||
| IL-13 | ** | ** | — | 0.457 | 0.416 | 0.408 | ||||||
| Eotaxin | * | — | 0.535 | 0.746 | 0.859 | |||||||
| IP-10 | ** | ** | ** | — | 0.643 | |||||||
| MCP-1 | ** | ** | * | * | ** | — | 0.139 | |||||
| MIP-1β | * | ** | ** | * | * | * | * | — | ||||
| VEGF | ** | ** | * | ** | — | |||||||
BCVA was converted to logMAR units (logMAR VA) for statistical analysis. R; multiple correlation coefficient, R2; coefficient of determination, β-coefficient; standardized partial regression coefficient, Std. Error; standard error. rs; Spearman correlation coefficient, *P < 0.05.